UCLA Finds Genetic Key to Personalized Weight Loss Drugs

Scientists just cracked a major code in personalized medicine, and it could change how millions of people receive treatment for everything from diabetes to weight loss.

UCLA Health researchers analyzed genetic data from 93,936 patients representing 36 different ancestry groups across Los Angeles, one of the world's most diverse cities. What they found could revolutionize how doctors prescribe medications.

The study, published in Cell, revealed something remarkable about GLP-1 drugs like Ozempic and Wegovy. For the first time, researchers showed that a person's genes can predict how well they'll lose weight on these medications. They even identified a specific gene called PTPRU that influences treatment response.

"This isn't a small lab finding," said Dr. Daniel Geschwind, who leads UCLA's ATLAS program. "ATLAS represents a sweeping cross-section of real patients, making its discoveries directly translatable to the groups of people medicine has historically left behind."

The diversity matters tremendously. Most genetic studies have focused heavily on people of European ancestry, leaving gaps in knowledge for everyone else. UCLA's biobank includes Armenian, Filipino, Mexican American, Ashkenazi Jewish, Iranian Jewish, and many other populations that rarely get represented in research.

This inclusive approach paid off with discoveries that would have been impossible in less diverse studies. Researchers found new genetic links to peripheral vascular disease in African individuals and cholesterol variations in Ashkenazi Jewish participants. For Mexican and South American populations, they identified increased risks for adverse hormonal therapy effects.

The team also tested polygenic risk scores, which estimate disease likelihood based on genetic variants. The results were encouraging. Many participants with high genetic risk scores for type 1 diabetes had actually been diagnosed, suggesting these scores could soon help doctors predict and prevent diseases before they develop.

The Ripple Effect

This research demonstrates how studying diverse populations benefits everyone. When scientists understand how genetics influence drug response across all ancestry groups, they can help doctors choose the right medication at the right dose for each patient, the first time.

The findings about weight loss medications are particularly timely as millions of Americans consider GLP-1 drugs. Knowing who will respond best could save patients time, money, and frustration while improving health outcomes.

Lead author Dr. Roni Haas emphasized that UCLA Health's location in Los Angeles County, home to 9.6 million people from countless backgrounds, creates a unique opportunity. The biobank reflects this real-world diversity while keeping clinical care consistent, making comparisons between groups more reliable.

The research team is already running pilot studies to bring these discoveries into clinical practice. Soon, your genetic profile might help your doctor choose which medications will work best for your unique biology.

Medicine is finally catching up to what patients have known all along: we're all different, and our treatments should reflect that reality.